A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

IntroductionLurbinectedin is a selective inhibitor of oncogenic transcription U.S. Food and Drug Administration (FDA)-approved for patients with relapsed small cell lung cancer (SCLC) as monotherapy at 3.2 mg/m2 every 3 weeks (q3wk). ATLANTIS was a phase 3 study in SCLC with lurbinectedin 2.0 mg/m2...

Full description

Bibliographic Details
Main Authors: Salvador Fudio, Laura Pérez-Ramos, Eduardo Asín-Prieto, Ali Zeaiter, Rubin Lubomirov
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
lurbinectedin
SCLC
exposure-response
modeling
simulation
Atlantis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1152371/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1152371/full

Similar Items